Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease. Vernero M, Ribaldone DG, Cariti C, Ribero S, et al. J Dermatol 2020;47:e216-e217.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Vernero M, Ribaldone DG, Cariti C, Ribero S, et al. Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease. J Dermatol 2020;47:e216-e217.
PMID: 32347562